These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 37897262)
41. Construction of a Novel Disulfidptosis-Related lncRNA Prognostic Signature in Pancreatic Cancer. Xing F; Qin Y; Xu J; Wang W; Zhang B Mol Biotechnol; 2024 Sep; 66(9):2396-2414. PubMed ID: 37733182 [TBL] [Abstract][Full Text] [Related]
42. Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer. Mulati Y; Lai C; Luo J; Hu J; Xu X; Kong D; Xiao Y; Liu C; Xu K BMC Cancer; 2024 Jan; 24(1):44. PubMed ID: 38191330 [TBL] [Abstract][Full Text] [Related]
43. Prognosis Signature of Cuprotosis-Related lncRNAs Associated with Kidney Renal Clear Cell Carcinoma. Gao Y; Jia Z Genet Res (Camb); 2022; 2022():6004852. PubMed ID: 36474620 [TBL] [Abstract][Full Text] [Related]
44. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma. Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955 [TBL] [Abstract][Full Text] [Related]
45. A long non-coding RNA signature to improve prognostic prediction in clear cell renal cell carcinoma. Zhang J; Zhang X; Piao C; Bi J; Zhang Z; Li Z; Kong C Biomed Pharmacother; 2019 Oct; 118():109079. PubMed ID: 31351427 [TBL] [Abstract][Full Text] [Related]
46. Comprehensive analysis of disulfidptosis-related genes: a prognosis model construction and tumor microenvironment characterization in clear cell renal cell carcinoma. Yi B; Wei X; Liu D; Jing L; Xu S; Zhang M; Liang Z; Liu R; Zhang Z Aging (Albany NY); 2024 Feb; 16(4):3647-3673. PubMed ID: 38358909 [TBL] [Abstract][Full Text] [Related]
47. A Novel Tumor Mutation Burden Related lncRNA Signature Identified Prognosis and Tumor Immune Microenvironment Features in Clear Cell Renal Cell Carcinoma. Lin L; Wu XH; Zhu JM; Chen SH; Chen YH; Lin F; Xue XY; Wei Y; Xu N; Zheng QS; Sun XL Comb Chem High Throughput Screen; 2023; 26(8):1503-1518. PubMed ID: 36165528 [TBL] [Abstract][Full Text] [Related]
48. Development and validation of a novel 5 cuproptosis-related long noncoding RNA signature to predict diagnosis, prognosis, and drug therapy in clear cell renal cell carcinoma. Chen Y; Hu W; Wei X; Zhang L; Shao Y; Tian J; Wang D; Wu B Transl Androl Urol; 2023 Apr; 12(4):622-641. PubMed ID: 37181235 [TBL] [Abstract][Full Text] [Related]
49. A novel necroptosis-related long noncoding RNA model for predicting clinical features, immune characteristics, and therapeutic response in clear cell renal cell carcinoma. Zhang L; Chen Y; Hu W; Wu B; Ye L; Wang D; Bai T Front Immunol; 2023; 14():1230267. PubMed ID: 37600792 [TBL] [Abstract][Full Text] [Related]
50. The clinical significance, immune infiltration, and tumor mutational burden of angiogenesis-associated lncRNAs in kidney renal clear cell carcinoma. Zhang W; Liu Z; Wang J; Geng B; Hou W; Zhao E; Li X Front Immunol; 2022; 13():934387. PubMed ID: 35958561 [TBL] [Abstract][Full Text] [Related]
51. Based on disulfidptosis, revealing the prognostic and immunological characteristics of renal cell carcinoma with tumor thrombus of vena cava and identifying potential therapeutic target AJAP1. Yang L; Liu J; Li S; Liu X; Zheng F; Xu S; Fu B; Xiong J J Cancer Res Clin Oncol; 2023 Sep; 149(12):9787-9804. PubMed ID: 37247081 [TBL] [Abstract][Full Text] [Related]
52. Construction and experimental validation of a signature for predicting prognosis and immune infiltration analysis of glioma based on disulfidptosis-related lncRNAs. Guo Y; Jiang Z; Chen Q; Xie D; Zhou Y; Yin W; Wang Z; Wang B; Ren C; Jiang X Front Immunol; 2023; 14():1291385. PubMed ID: 38022537 [TBL] [Abstract][Full Text] [Related]
53. Downregulation of long non-coding RNA ENSG00000241684 is associated with poor prognosis in advanced clear cell renal cell carcinoma. Su H; Wang H; Shi G; Zhang H; Sun F; Ye D Eur J Surg Oncol; 2018 Jun; 44(6):840-846. PubMed ID: 29433989 [TBL] [Abstract][Full Text] [Related]
54. Clinicopathological and Prognostic Value of Necroptosis-Associated lncRNA Model in Patients with Kidney Renal Clear Cell Carcinoma. Gu J; He Z; Huang Y; Luan T; Chen Z; Wang J; Ding M Dis Markers; 2022; 2022():5204831. PubMed ID: 35664432 [TBL] [Abstract][Full Text] [Related]
55. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer. Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096 [TBL] [Abstract][Full Text] [Related]
56. Identification of exosomes-related lncRNAs in clear cell renal cell carcinoma based on Bayesian spike-and-slab lasso approach. Niu Y; Jia X; Wang N; Yuan M; Dong A; Yang Y; Shi X Funct Integr Genomics; 2023 Feb; 23(1):62. PubMed ID: 36805328 [TBL] [Abstract][Full Text] [Related]
57. Development and validation of a novel disulfidptosis-related lncRNAs signature in patients with HPV-negative oral squamous cell carcinoma. Yang F; Niu X; Zhou M; Li W Sci Rep; 2024 Jun; 14(1):14436. PubMed ID: 38910181 [TBL] [Abstract][Full Text] [Related]
58. Identifying molecular subtypes and tumor microenvironment infiltration signatures in kidney renal clear cell carcinoma based on stemness-associated disulfidptosis genes by integrating machine learning, single-cell analyses and experimental validation. Liu H; Liang X; Tang G; Wang X; Wang Z; Tong L; Mao Q; Ma J; Wu J Heliyon; 2024 Feb; 10(4):e26094. PubMed ID: 38390172 [TBL] [Abstract][Full Text] [Related]
59. Identification of disulfidptosis-related subtypes and development of a prognosis model based on stacking framework in renal clear cell carcinoma. Peng K; Wang N; Liu Q; Wang L; Duan X; Xie G; Li J; Ding D J Cancer Res Clin Oncol; 2023 Nov; 149(15):13793-13810. PubMed ID: 37530800 [TBL] [Abstract][Full Text] [Related]
60. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma. Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]